... San Antonio Breast Cancer Symposium. 12/11/24 7:05:00 AM ET. $CELC ... biotech company's first drug. His significant commercial experience at ...
News
- Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in ...
- Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination
... San Antonio Breast Cancer Symposium on Wednesday. Already registered ... Krystal Biotech Expects CHMP Opinion on Skin Condition Gene Therapy in Early ...
- Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational ...
The clinical results along with new biomarker studies will be presented in a poster session at the upcoming San Antonio Breast Cancer Symposium (SABCS) ...
- Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and ...
... San Antonio Breast Cancer Symposium highlighting the activity the ... Sarepta, Biotech's Regulatory Go-Getter, Signs Standout Rare Disease Deal.
- Celcuity's Breast Cancer Drug Shows Breakthrough 77-Month Survival Data in Clinical Trial
The data was presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2024. ... Celcuity is a clinical-stage biotechnology ...